Prescription ·Strong evidence ·Reviewed May 2026
The only selective COX-2 inhibitor currently available in the U.S., celecoxib provides anti-inflammatory and analgesic effects with a significantly lower risk of GI ulceration and bleeding compared to nonselective NSAIDs. It is used for osteoarthritis, rheumatoid arthritis, ankylosing spondylitis, acute pain, and dysmenorrhea.
The bottom line
Evidence rating strong. Most-documented uses: pain and inflammation relief in osteoarthritis, treatment of rheumatoid arthritis, reduced gi bleeding risk compared to nonselective nsaids. 10 sources indexed (2016–2025), with 8 interaction records on file.
Core mechanism
Selectively inhibits cyclooxygenase-2 (COX-2) at therapeutic concentrations, reducing prostaglandin synthesis at sites of inflammation while largely sparing COX-1-dependent prostaglandin production in the gastric mucosa and platelets. This selectivity accounts for the improved GI safety profile, though cardiovascular risk remains a concern.
Can be taken with or without food; taking with food may slow absorption but does not affect total bioavailability
Both celecoxib and curcumin inhibit COX-2. Combined use may provide additive anti-inflammatory effects but also increases the risk of GI and cardiovascular side effects.
Recommendation: Use low-dose curcumin if combining. The additive COX-2 inhibition may increase cardiovascular and GI risk.
Celecoxib generally causes fewer upper GI ulcers than many nonselective NSAIDs, but alcohol can still increase GI irritation and bleeding risk. The risk becomes more clinically important with higher celecoxib doses, prior ulcer disease, older age, or combined aspirin use. Alcohol also worsens dehydration, which can increase NSAID kidney risk.
Recommendation: Avoid heavy alcohol use while taking celecoxib. If you have ulcer history or take low-dose aspirin with celecoxib, ask your clinician whether you need a stomach-protection strategy.
Celecoxib can still affect kidney prostaglandins and potassium balance despite its COX-2 selectivity. Potassium supplements increase the potassium load and can contribute to hyperkalemia when renal excretion is reduced. The combination is most risky with kidney disease, dehydration, diabetes, older age, ACE inhibitors, ARBs, or potassium-sparing diuretics.
Recommendation: Do not add potassium supplements to celecoxib without a reason and a monitoring plan. Check serum potassium and kidney function if you need both, and avoid celecoxib during dehydration unless your clinician advises otherwise.
Ginkgo biloba may add bleeding risk to celecoxib, particularly in people who also take aspirin or have ulcer history. Celecoxib is more GI-sparing than many NSAIDs, but it does not eliminate GI bleeding risk. Ginkgo has case reports of spontaneous bleeding and uncertain but plausible platelet effects.
Recommendation: Avoid ginkgo if you take celecoxib with aspirin or other bleeding-risk medicines. If used together, watch for unusual bruising, nosebleeds, black stools, or new severe headache.
Nattokinase may add fibrinolytic effects to celecoxib-related bleeding risk, especially when celecoxib is used with aspirin or in patients with ulcer history. Celecoxib alone is less platelet-active than nonselective NSAIDs, but it can still contribute to GI injury. Nattokinase has human evidence of coagulation and thrombolysis effects.
Recommendation: Avoid nattokinase if you take celecoxib with aspirin or other blood-thinning medicines. Stop nattokinase before procedures unless your clinician has specifically approved continued use.
Curcumin phytosome may add antiplatelet activity to celecoxib in people with additional bleeding risks. Celecoxib is less platelet-active than many NSAIDs, but GI bleeding risk is not zero, especially with aspirin or ulcer history. The phytosome formulation is relevant because it can increase curcumin absorption compared with standard preparations.
Recommendation: Avoid high-dose curcumin phytosome if you take celecoxib with aspirin or have a bleeding or ulcer history. If both are used, monitor for bruising, nosebleeds, black stools, or vomiting blood.
Fish oil has mild antiplatelet effects and may add bleeding risk to celecoxib in higher-risk situations. Modern randomized-trial evidence suggests usual omega-3 doses do not greatly increase bleeding, but high-dose EPA/DHA or combination with aspirin can matter. The risk is most relevant around procedures or in people with prior GI bleeding.
Recommendation: Use caution with high-dose fish oil while taking celecoxib, especially if you also take aspirin. Pause fish oil before procedures if your clinical team requests it, and report black stools, vomiting blood, or unusual bruising.
Resveratrol may increase celecoxib exposure and also has antiplatelet effects, creating a plausible safety concern. A human pharmacokinetic study found celecoxib disposition changed with resveratrol co-administration. The combination is most relevant with higher celecoxib doses, bleeding risk, cardiovascular risk, or other medicines affected by CYP pathways.
Recommendation: Use caution with resveratrol supplements while taking celecoxib, especially at high doses. Watch for celecoxib adverse effects such as stomach pain, edema, blood pressure worsening, bruising, or black stools.
Numbered references. Citations throughout the page link here.
Beaudart C, Brabant C, Alokail M et al.. Current Evidence on Celecoxib Safety in the Management of Chronic Musculoskeletal Conditions: An Umbrella Review. Drugs. 2025
Gędek A, Szular Z, Antosik AZ et al.. Celecoxib for Mood Disorders: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Journal of clinical medicine. 2023
Li L, Zhang Y, Qin L. Effect of celecoxib plus standard chemotherapy on cancer prognosis: A systematic review and meta-analysis. European journal of clinical investigation. 2023
Wang Z, Wu Q, Wang Q. Effect of celecoxib on improving depression: A systematic review and meta-analysis. World journal of clinical cases. 2022
Wan R, Li P, Jiang H. The efficacy of celecoxib for pain management of arthroscopy: A meta-analysis of randomized controlled trials. Medicine. 2019
Zheng W, Cai DB, Yang XH et al.. Adjunctive celecoxib for schizophrenia: A meta-analysis of randomized, double-blind, placebo-controlled trials. Journal of psychiatric research. 2017
Xu C, Gu K, Yasen Y et al.. Efficacy and Safety of Celecoxib Therapy in Osteoarthritis: A Meta-Analysis of Randomized Controlled Trials. Medicine. 2016
This page is educational. Do not start, stop, or change a supplement or medication based on it without checking with a qualified healthcare professional.
Use this with your stack
Add it to your stack, see how it interacts with everything else you take, and get a Stack Score that updates the moment it does.
NutriStack is an informational and organizational tool, not a medical service, and not a substitute for professional advice. Always consult a qualified healthcare professional before starting, stopping, or changing any supplement or medication.
NutriStack